开立医疗
(300633)
| 流通市值：48.25亿 | | | 总市值：78.81亿 |
| 流通股本：2.60亿 | | | 总股本：4.25亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,053,322,517.14 | 480,719,375.08 | 2,308,908,666.51 | 1,459,311,230.15 |
| 营业收入 | 1,053,322,517.14 | 480,719,375.08 | 2,308,908,666.51 | 1,459,311,230.15 |
| 二、营业总成本 | 1,087,875,025.74 | 523,253,650.33 | 2,183,569,025.01 | 1,499,658,882.65 |
| 营业成本 | 412,080,085.05 | 185,354,037.41 | 877,685,277.8 | 578,416,133.46 |
| 税金及附加 | 9,510,349.57 | 5,414,489.52 | 21,269,857.24 | 8,947,942.8 |
| 销售费用 | 338,545,716.41 | 154,974,275.39 | 675,489,904.28 | 478,867,249.35 |
| 管理费用 | 73,990,531.55 | 41,227,695.58 | 146,257,636.8 | 104,951,088.87 |
| 研发费用 | 228,596,059.96 | 115,341,403.68 | 495,778,393.21 | 366,780,072.05 |
| 财务费用 | 25,152,283.2 | 20,941,748.75 | -32,912,044.32 | -38,303,603.88 |
| 其中:利息费用 | 2,172,202.11 | 934,089.38 | 4,158,721.83 | 3,453,380.04 |
| 其中:利息收入 | 17,561,638.33 | 2,645,551.61 | 35,631,786.52 | 29,219,319.98 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 590,177.8 | 51,340.14 | 163,727.82 | 56,125.16 |
| 加:投资收益 | 377,945.08 | 261,512.18 | 2,195,770.34 | 2,078,228.25 |
| 资产处置收益 | - | - | 30,736.87 | - |
| 资产减值损失(新) | -11,277,437.15 | - | -42,213,984.81 | -13,444,560.78 |
| 信用减值损失(新) | 2,440,816.53 | 2,178,403.46 | -12,254,268.46 | 6,170,470.06 |
| 其他收益 | 50,609,230.09 | 23,231,583.13 | 92,021,157.25 | 55,078,825.39 |
| 四、营业利润 | 8,188,223.75 | -16,811,436.34 | 165,282,780.51 | 9,591,435.58 |
| 加:营业外收入 | 335,428.68 | 253,313.12 | 1,229,754.75 | 1,264,104.56 |
| 减:营业外支出 | 326,481.52 | 123,868.46 | 2,321,545.33 | 1,898,288.71 |
| 五、利润总额 | 8,197,170.91 | -16,681,991.68 | 164,190,989.93 | 8,957,251.43 |
| 减:所得税费用 | -5,579,090.21 | -5,072,557.25 | -33,089,087.37 | -24,553,810.68 |
| 六、净利润 | 13,776,261.12 | -11,609,434.43 | 197,280,077.3 | 33,511,062.11 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 13,776,261.12 | -11,609,434.43 | 197,280,077.3 | 33,511,062.11 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 13,776,261.12 | -11,609,434.43 | 197,280,077.3 | 33,511,062.11 |
| 扣除非经常损益后的净利润 | 2,485,237.27 | -14,290,110.04 | 180,275,203.05 | 23,991,020.02 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.03 | -0.03 | 0.46 | 0.08 |
| (二)稀释每股收益 | 0.03 | -0.03 | 0.46 | 0.08 |
| 八、其他综合收益 | -982,567.04 | 2,090,055.92 | -3,135,975.42 | 9,759,243.34 |
| 归属于母公司股东的其他综合收益 | -982,567.04 | 2,090,055.92 | -3,135,975.42 | 9,759,243.34 |
| 九、综合收益总额 | 12,793,694.08 | -9,519,378.51 | 194,144,101.88 | 43,270,305.45 |
| 归属于母公司股东的综合收益总额 | 12,793,694.08 | -9,519,378.51 | 194,144,101.88 | 43,270,305.45 |
| 公告日期 | 2026-08-22 | 2026-04-29 | 2026-04-17 | 2025-10-29 |
| 审计意见(境内) | | | 标准无保留意见 | |